Cynata was founded in 2014 with a vision of delivering advanced cellular therapies to patients with complex diseases. Since then, Cynata has developed its patented Cymerus™ manufacturing technology and has generated strong scientific and clinical evidence supporting the clinical potential of its Cymerus™-based therapeutics.

Mission

Our mission is to develop safe and effective cell therapies for the treatment of patients with complex diseases and to make these therapeutics available to those in need.

Vision

Our vision is to revolutionize cellular therapy by providing products that are safe, accessible and cost-effective.

Key Team

Stewart James Washer (Non-Independent Non-Executive Director)

Paul Kevin Wotton (Independent Non-Executive Director)

Darryl Maher (Independent Non-Executive Director)

Janine Louise Rolfe (Independent Non-Executive Director)

Recognition and Awards

Cynata has received numerous awards for its innovative therapeutic solutions, including the ISSCR’s Edward G. Rheinwald award for excellence in stem cell research and iGEM's Grand Prize for best project in Regenerative Medicine.

References

https://in.investing.com/equities/cynata-therapeutics-ltd

https://www.crunchbase.com/organization/cynata

cynata.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Geoffrey Edward Duncan Brooke (Independent Non-Executive Chairman)

Ross Alexander MacDonald (MD, CEO & Executive Director)

Igor Slukvin (Member of Scientific Advisory Board)

Products/ Services

Biotechnology, Health Care, Life Science

Number of Employees

0 - 50

Headquarters

Armadale, Victoria, Australia

Established

2003

Traded as

ASX:CYP

Social Media

URL

cynata.com

Last updated: Tue Feb 25 2025

We value your privacy

Cynata

Table of content

Summary

History

Mission

Vision

Key Team

Recognition and Awards

References